PUMA BIOTECHNOLOGY, INC.
PBYINasdaq
$8.53
↑ +1.5%Jul 17 close · end-of-day
Price
1Y↑ +148.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$433.7M
Enterprise Value
$343.4M
P/E
17.8
P/S
1.9
P/B
3.4
EV/EBITDA
8.5
PEG
—
FCF Yield
12.4%
Dividend Yield
—
Revenue (TTM)
$227.2M
Net Income (TTM)
$24.4M
Free Cash Flow (TTM)
$53.6M
Gross Margin
—
Operating Margin
13.0%
Net Margin
10.7%
ROE
19.0%
ROIC
61.1%
Debt / Equity
0.1
Net Cash
$90.3M
Return 1Y
+153.9%
Company profile
Puma Biotechnology, Inc. focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd.
- CEO
- Alan H. Auerbach
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 200
- Headquarters
- California
- Website
- pumabiotechnology.com
Management & directors
- Auerbach Alan HPresident and CEO
- Hunt Douglas MSee Remarks
- Nougues Maximo FChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
PBYI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$44.8M↓ -2.6%
Diluted EPS-$0.07↓ -216.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $225.1M | $253.2M | $228.0M | $235.6M | $230.5M | $228.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$30.4M | $1.3M | $23.7M | $32.6M | $31.0M | $37.3M |
| Net income | -$60.0M | $29.1M | $2,000.00 | $21.6M | $30.3M | $31.1M |
| Diluted EPS | -$1.52 | -$0.72 | $0.00 | $0.45 | $0.62 | $0.61 |
| Operating cash flow | $773,000.00 | $20.6M | -$15.8M | $27.0M | $38.9M | $41.8M |
| Free cash flow | $727,000.00 | $20.6M | -$15.8M | $26.9M | $38.9M | $41.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -13.5% | 0.5% | 10.4% | 13.9% | 13.4% | 16.3% |
| Net margin | -26.7% | 11.5% | 0.0% | 9.2% | 13.1% | 13.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.1M | $80.5M | $59.1M | $46.0M | $52.4M | $54.5M | $75.5M | $44.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.2M | $22.1M | $13.4M | $4.0M | $6.6M | $9.6M | $17.1M | -$3.8M |
| Net income | -$4.5M | $20.3M | $19.3M | $3.0M | $5.9M | $8.8M | $13.4M | -$3.8M |
| Diluted EPS | -$0.09 | $0.41 | $0.40 | $0.06 | $0.12 | $0.17 | $0.26 | -$0.07 |
| Operating cash flow | $1.0M | $11.0M | $15.6M | $3.6M | $14.1M | $9.7M | $14.4M | $15.4M |
| Free cash flow | $1.0M | $11.0M | $15.6M | $3.6M | $14.1M | $9.7M | $14.4M | $15.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -4.6% | 27.4% | 22.6% | 8.7% | 12.7% | 17.6% | 22.7% | -8.5% |
| Net margin | -9.6% | 25.2% | 32.7% | 6.5% | 11.2% | 16.2% | 17.8% | -8.4% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | AUERBACH ALAN H· President and CEO | Sale | 44,058 | $8.26 | $364,051.25 | filing |
| 2026-07-06 | NOUGUES MAXIMO F· Chief Financial Officer | Sale | 9,386 | $8.26 | $77,556.52 | filing |
| 2026-07-06 | HUNT DOUGLAS M· See Remarks | Sale | 8,460 | $8.26 | $69,904.98 | filing |
| 2026-06-12 | Senderowicz Adrian | Sale | 27,000 | $7.20 | $194,310.90 | filing |
| 2026-06-12 | MOYES JAY M | Sale | 22,000 | $7.22 | $158,796.00 | filing |
| 2026-06-12 | Dorval Allison | Sale | 11,610 | $7.20 | $83,579.23 | filing |
| 2026-06-12 | WILSON TROY EDWARD | Sale | 10,800 | $7.20 | $77,748.12 | filing |
| 2026-06-12 | Stuglik Brian M | Sale | 8,100 | $7.20 | $58,311.09 | filing |
| 2026-06-11 | Dorval Allison | Award | 27,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | WILSON TROY EDWARD | Award | 27,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | Stuglik Brian M | Award | 27,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | Senderowicz Adrian | Award | 27,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | MILLER MICHAEL PATRICK | Award | 27,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | MOYES JAY M | Award | 27,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | Cesano Alessandra | Award | 27,000 | $0.00 | $0.00 | filing |
| 2026-02-18 | AUERBACH ALAN H· President and CEO | Award | 159,778 | $0.00 | $0.00 | filing |
| 2026-02-18 | HUNT DOUGLAS M· See Remarks | Award | 49,394 | $0.00 | $0.00 | filing |
| 2026-02-18 | NOUGUES MAXIMO F· Chief Financial Officer | Award | 46,739 | $0.00 | $0.00 | filing |
| 2026-01-07 | AUERBACH ALAN H· President and CEO | Sale | 18,012 | $5.88 | $105,892.55 | filing |
| 2026-01-07 | NOUGUES MAXIMO F· Chief Financial Officer | Sale | 6,405 | $5.88 | $37,655.00 | filing |
| 2026-01-07 | HUNT DOUGLAS M· See Remarks | Sale | 5,014 | $5.88 | $29,477.31 | filing |
| 2026-01-06 | AUERBACH ALAN H· President and CEO | Sale | 16,938 | $5.84 | $98,985.67 | filing |
| 2026-01-06 | NOUGUES MAXIMO F· Chief Financial Officer | Sale | 4,540 | $5.84 | $26,531.76 | filing |
| 2026-01-06 | HUNT DOUGLAS M· See Remarks | Sale | 3,973 | $5.84 | $23,218.21 | filing |
| 2025-11-11 | MILLER MICHAEL PATRICK | Sale | 20,000 | $4.86 | $97,228.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.